帕唑帕尼治疗遗传性出血性毛细血管扩张症相关鼻出血和胃肠道出血
本文报告了单中心、回顾性帕唑帕尼真实世界应用情况,纳入6例遗传性出血性毛细血管扩张症(HHT)相关鼻出血和/或胃肠道出血患者,观察帕唑帕尼的安全性/有效性;结果显示血红蛋白水平改善,铁剂输注和红细胞输血需求减少;作者认为帕唑帕尼可能是标准治疗难治的HHT鼻出血或胃肠道出血患者的一个合理选择。
要点
- 帕唑帕尼在6例HHT相关中度至重度出血患者中显示血红蛋白水平改善。
- 帕唑帕尼治疗后铁剂输注和红细胞输血需求减少。
- 作者认为帕唑帕尼可能是标准治疗难治的HHT鼻出血或胃肠道出血患者的合理选择。
核心结论
- 帕唑帕尼可能是标准治疗难治的HHT鼻出血或胃肠道出血患者的一个合理选择。
研究设计与样本
- 单中心、回顾性观察性分析,评估2019年1月1日至2023年6月14日期间确诊HHT相关鼻出血和/或胃肠道出血患者使用帕唑帕尼的安全性/有效性。
- 查询Indiana Hemophilia and Thrombosis机构电子病历,纳入因HHT接受帕唑帕尼治疗≥3个月的患者,共6例。
- 患者数据来自患者记录、医师/护理记录和值班记录;机构审查委员会批准作为豁免研究进行数据提取。
主要发现
- 6例HHT中度至重度出血患者真实世界使用帕唑帕尼后,血红蛋白水平改善。
- 6例HHT中度至重度出血患者真实世界使用帕唑帕尼后,铁剂输注减少。
- 6例HHT中度至重度出血患者真实世界使用帕唑帕尼后,红细胞输血需求减少。
临床怎么用
- 作者认为,帕唑帕尼可能是标准治疗难治的HHT鼻出血或胃肠道出血患者的一个合理选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hereditary hemorrhagic telangiectasia (HHT) is a bleeding disorder characterized by arteriovenous malformations, commonly presenting with epistaxis and gastrointestinal (GI) bleeding. Bleeding symptoms may be difficult to manage and may become life-threatening, with many patients developing dependence on parenteral iron and/or blood transfusion. There is a growing body of evidence that antiangiogenic therapies may be effective in management of bleeding symptoms, presumably targeting pathogenic HHT pathways such as vascular endothelial growth factor receptor. OBJECTIVES: To report single-center, retrospective real-world use of pazopanib, an orally administered tyrosine kinase inhibitor that blocks vascular endothelial growth factor receptors, in 6 patients with HHT-associated epistaxis and/or GI bleeding. METHODS: A retrospective observational analysis was performed to assess the safety/efficacy of pazopanib use in patients with confirmed HHT-associated epistaxis and/or GI bleeding between January 1, 2019, and June 14, 2023. The Indiana Hemophilia and Thrombosis institutional electronic medical record was queried for HHT patients who were treated with pazopanib for ≥3 months. Patient data were obtained from patient documentation, physician/nursing notes, and on-call documentation. Institutional review board approval was obtained for data pull as an exempt study. RESULTS: Our observations on the real-world use of pazopanib in 6 HHT patients with moderate-to-severe bleeding showed improvement in hemoglobin levels, with reduction in iron infusions and red blood cell transfusion requirement. CONCLUSION: Pazopanib may be a reasonable option for patients with HHT with epistaxis or gastrointestinal bleeding that are refractory to standard treatment.
引用
- Lewandowska MD, Gordon S, Betbadal A, et al. Pazopanib in treatment of hereditary hemorrhagic telangiectasia-related epistaxis and gastrointestinal bleeding. J Thromb Haemost. 2024. PMID: 39454885. doi:10.1016/j.jtha.2024.10.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。